Τίτλος:
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
D-VMP is a novel treatment for transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM). D-VMP significantly prolonged PFS versus VMP in the ALCYONE trial. The FIRST trial investigated Rd given in 28-day cycles until disease progression, Rd for 18 cycles, and MPT for 12 cycles for TIE NDMM. As no randomized controlled trials comparing D-VMP to standard-of-care regimens such as those in FIRST are available, an MAIC was performed to assess relative OS and PFS for D-VMP from ALYCONE and Rd continuous, Rd 18, and MPT from FIRST. Individual patient data for D-VMP in ALCYONE were weighted to match aggregated baseline patient characteristics for each arm of FIRST. D-VMP significantly improved OS versus MPT and Rd 18, with a trend favoring D-VMP versus Rd continuous. D-VMP performed significantly better than all FIRST comparators for PFS. This MAIC demonstrates OS and PFS benefits for D-VMP versus Rd continuous, Rd 18, and MPT. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Dimopoulos, M.A.
Cavo, M.
Mateos, M.-V.
Facon, T.
Heeg, B.
van Beekhuizen, S.
Gebregergish, S.B.
Nair, S.
Pisini, M.
Lam, A.
Slavcev, M.
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
antineoplastic agent; bortezomib; daratumumab; dexamethasone; immunoglobulin G; lenalidomide; melphalan; prednisone; thalidomide; antineoplastic agent; bortezomib; daratumumab; dexamethasone; lenalidomide; melphalan; monoclonal antibody; prednisone; thalidomide, aged; Article; body surface; cancer combination chemotherapy; cancer patient; cancer survival; clinical outcome; comparative study; continuous infusion; controlled study; disease exacerbation; female; follow up; human; major clinical study; male; multiple cycle treatment; multiple myeloma; overall survival; priority journal; progression free survival; randomized controlled trial; treatment outcome, Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome
DOI:
10.1080/10428194.2019.1682571
